WuXi Biologics (Cayman) Dirección

Dirección controles de criterios 1/4

El CEO de WuXi Biologics (Cayman)'s es Chris Chen , nombrado en Jan 2016, tiene una permanencia de 8.25 años. compensación anual total es CN¥78.67M, compuesta por 3.8% salario y 96.2% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.32% de las acciones de la empresa, por valor de HK$170.05M. La antigüedad media del equipo directivo y de la junta directiva es de 2.4 años y 6.6 años, respectivamente.

Información clave

Chris Chen

Chief Executive Officer (CEO)

CN¥96.9m

Compensación total

Porcentaje del salario del CEO	4.1%
Permanencia del CEO	8.3yrs
Participación del CEO	0.3%
Permanencia media de la dirección	1.7yrs
Promedio de permanencia en la Junta Directiva	6.7yrs

Actualizaciones recientes de la dirección

Recent updates

Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly

Apr 15

Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge

Mar 04

Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade

Dec 08

These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well

Aug 26

WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate

Aug 10

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?

Jun 19

Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

May 12

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Mar 25

At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?

Mar 13

Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?

Feb 13

An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued

Jan 30

Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?

Dec 09

Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching

Nov 20

With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case

Nov 08

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?

Oct 27

WuXi Biologics (Cayman) (HKG:2269) Seems To Use Debt Quite Sensibly

Sep 08

Is Now The Time To Look At Buying WuXi Biologics (Cayman) Inc. (HKG:2269)?

Aug 15

We Ran A Stock Scan For Earnings Growth And WuXi Biologics (Cayman) (HKG:2269) Passed With Ease

Aug 02

Estimating The Intrinsic Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

Jun 29

What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?

May 16

Here's Why I Think WuXi Biologics (Cayman) (HKG:2269) Might Deserve Your Attention Today

May 03

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Apr 21

An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 42% Undervalued

Mar 26

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Chris Chen en comparación con los beneficios de WuXi Biologics (Cayman)?
Fecha	Compensación total	Salario	Ingresos de la empresa
Dec 31 2023	CN¥97m	CN¥4m	CN¥3b
Sep 30 2023	n/a	n/a	CN¥4b
Jun 30 2023	n/a	n/a	CN¥4b
Mar 31 2023	n/a	n/a	CN¥4b
Dec 31 2022	CN¥79m	CN¥3m	CN¥4b
Sep 30 2022	n/a	n/a	CN¥4b
Jun 30 2022	n/a	n/a	CN¥4b
Mar 31 2022	n/a	n/a	CN¥4b
Dec 31 2021	CN¥51m	CN¥3m	CN¥3b
Sep 30 2021	n/a	n/a	CN¥3b
Jun 30 2021	n/a	n/a	CN¥3b
Mar 31 2021	n/a	n/a	CN¥2b
Dec 31 2020	CN¥31m	CN¥3m	CN¥2b
Sep 30 2020	n/a	n/a	CN¥1b
Jun 30 2020	n/a	n/a	CN¥1b
Mar 31 2020	n/a	n/a	CN¥1b
Dec 31 2019	CN¥25m	CN¥3m	CN¥1b
Sep 30 2019	n/a	n/a	CN¥922m
Jun 30 2019	n/a	n/a	CN¥831m
Mar 31 2019	n/a	n/a	CN¥731m
Dec 31 2018	CN¥20m	CN¥2m	CN¥631m
Sep 30 2018	n/a	n/a	CN¥520m
Jun 30 2018	n/a	n/a	CN¥410m
Mar 31 2018	n/a	n/a	CN¥331m
Dec 31 2017	CN¥24m	CN¥2m	CN¥253m

Compensación vs. Mercado: La compensación total de Chris($USD10.86M) está por encima de la media de empresas de tamaño similar en el mercado Hong Kong ($USD923.19K).

Compensación vs. Ingresos: La compensación de Chris ha aumentado más de un 20%, mientras que los beneficios de la empresa han caído más de un 20% en el último año.

CEO

Chris Chen (50 yo)

8.3yrs

Permanencia

CN¥96,911,000

Compensación

Dr. Zhisheng Chen, also known as Chris, Ph.D. has been the Chief Executive Officer & Executive Director at WuXi Biologics (Cayman) Inc. since January 01, 2016 and since February 27, 2014 respectively. Dr....

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Ge Li	Founder & Chairman	10.3yrs	sin datos	sin datos
Zhisheng Chen	CEO & Executive Director	8.3yrs	CN¥96.91m	0.32% CN¥ 193.4m
Weichang Zhou	Honorary President of Global Biologics Development	9.1yrs	CN¥32.89m	0.0059% CN¥ 3.6m
Ming Tu	CFO & Executive VP	2.5yrs	sin datos	sin datos
Lihua Yu	COO & Senior VP	less than a year	sin datos	sin datos
Sherry Gu	Chief Technology Officer and Executive VP of Global Biologics Development Department	less than a year	sin datos	sin datos
Jijie Gu	Chief Scientific Officer & President of Global Biologics Research	no data	sin datos	sin datos
Lina Fan	Senior VP & Head of Investor Relations	less than a year	sin datos	sin datos
Cong Ding	VP & Head of Legal Department	no data	sin datos	sin datos
He Wang	Chief Compliance Officer	1.7yrs	sin datos	sin datos
Li Xiong	VP & Head of Global Human Resources	no data	sin datos	sin datos
Angus Scott Turner	Senior VP and Head of Global BD & Alliance Management	no data	sin datos	sin datos

1.7yrs

Permanencia media

55yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de 2269 no se considera experimentado ( 1.7 años antigüedad media), lo que sugiere un nuevo equipo.

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Ge Li	Founder & Chairman	10.3yrs	sin datos	sin datos
Zhisheng Chen	CEO & Executive Director	10.3yrs	CN¥96.91m	0.32% CN¥ 193.4m
Weichang Zhou	Honorary President of Global Biologics Development	8yrs	CN¥32.89m	0.0059% CN¥ 3.6m
Jackson Tai	Independent Non-Executive Director	less than a year	CN¥710.00k	0.00062% CN¥ 378.4k
James Larrick	Member of Scientific Advisory Board	6.3yrs	sin datos	sin datos
David D. Ho	Member of Scientific Advisory Board	6.3yrs	sin datos	sin datos
Wei-Shou Hu	Member of Scientific Advisory Board	6.3yrs	sin datos	sin datos
Ram Sasisekharan	Member of Scientific Advisory Board	6.3yrs	sin datos	sin datos
William Robert Keller	Independent Non-Executive Director	7yrs	CN¥906.00k	0.00053% CN¥ 323.4k
Yanling Cao	Non-Executive Director	8yrs	sin datos	sin datos
Yibing Wu	Non-Executive Director	8yrs	sin datos	sin datos
Kenneth Walton Hitchner	Independent Non-Executive Director	3.9yrs	CN¥933.00k	0.0049% CN¥ 3.0m

6.7yrs

Permanencia media

58.5yo

Promedio de edad

Junta con experiencia: La junta directiva de 2269 se considera experimentada (6.6 años de antigüedad promedio).

WuXi Biologics (Cayman) Dirección

Dirección controles de criterios 1/4

Información clave

Actualizaciones recientes de la dirección

Less than half of directors are independent

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Independent Non-Executive Director recently bought HK$3.0m worth of stock

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

CEO & Executive Director recently sold HK$6.0m worth of stock

Recent updates

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Here's Why WuXi Biologics (Cayman) (HKG:2269) Can Manage Its Debt Responsibly

Less than half of directors are independent

Consensus EPS estimates fall by 18%

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 19, 2024

Full year 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

WuXi Biologics (Cayman) Inc.(SEHK:2269) dropped from S&P International 700

Investor sentiment deteriorates as stock falls 16%

Why Investors Shouldn't Be Surprised By WuXi Biologics (Cayman) Inc.'s (HKG:2269) 25% Share Price Surge

WuXi Biologics (Cayman) Inc. to Report Q4, 2023 Results on Mar 26, 2024

Investor sentiment deteriorates as stock falls 18%

WuXi Biologics Successfully Completes First 1,6000L Manufacturing Run in Ireland

Investor sentiment deteriorates as stock falls 21%

WuXi Biologics Launches WuXia ADCC PLUS™ for the Development and Manufacturing of Afucosylated Antibodies that Elicit Enhanced ADCC Effect

Independent Non-Executive Director recently bought HK$3.0m worth of stock

WuXi Biologics Receives U.S. Patent for Proprietary Bispecific Antibody Technology Platform WuXiBody™

WuXi Biologics (Cayman) Inc. Announces Executive Changes, Effective March 31, 2024

Investor sentiment improves as stock rises 16%

Things Look Grim For WuXi Biologics (Cayman) Inc. (HKG:2269) After Today's Downgrade

WuXi Biologics (Cayman) Inc. (SEHK:2269) commences an Equity Buyback Plan for 424,841,177 shares, representing 10% of its issued share capital, under the authorization approved on June 27, 2023.

New minor risk - Share price stability

Consensus revenue estimates fall by 14%

Investor sentiment deteriorates as stock falls 28%

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

CEO & Executive Director recently sold HK$6.0m worth of stock

Wuxi Biologics Successfully Implements Fully Integrated Continuous Process with Breakthrough Productivity of 6 g/L/Day At Pilot Scale

Now 20% undervalued

Board Member recently sold HK$25m worth of stock

Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

Now 21% undervalued

WuXi Biologics Launches New High-Productivity Bioprocessing Platform WuXiUI™ for Cost-Effective Commercial Manufacturing and Desirable Product Quality

Investor sentiment improves as stock rises 16%

What Does WuXi Biologics (Cayman) Inc.'s (HKG:2269) Share Price Indicate?

These 4 Measures Indicate That WuXi Biologics (Cayman) (HKG:2269) Is Using Debt Reasonably Well

First half 2023 earnings released: EPS: CN¥0.55 (vs CN¥0.61 in 1H 2022)

Wuxi Biologics (Cayman) Inc. Announces Executive Changes

WuXi Biologics (Cayman) Inc. (HKG:2269) Shares Could Be 24% Below Their Intrinsic Value Estimate

WuXi Biologics (Cayman) Inc. to Report First Half, 2023 Results on Aug 23, 2023

CEO & Executive Director recently sold HK$4.6m worth of stock

Investor sentiment deteriorates as stock falls 20%

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Potentially Undervalued?

CEO & Executive Director recently sold HK$13m worth of stock

Now 21% undervalued after recent price drop

WuXi Biologics (Cayman) Inc., Annual General Meeting, Jun 15, 2023

WuXi Biologics (Cayman) Inc. Announces Demise of Ning Zhao, Non-Executive Director, Member of Remuneration Committee and Member of Environmental, Social and Governance Committee

Estimating The Fair Value Of WuXi Biologics (Cayman) Inc. (HKG:2269)

Now 22% undervalued after recent price drop

WuXi Biologics (Cayman) Inc. Announces Board and Board Committee Changes

Now 21% undervalued after recent price drop

Investor sentiment improves as stock rises 16%

Now 20% undervalued after recent price drop

Does WuXi Biologics (Cayman) (HKG:2269) Have A Healthy Balance Sheet?

Full year 2022 earnings: EPS misses analyst expectations

At HK$52.00, Is WuXi Biologics (Cayman) Inc. (HKG:2269) Worth Looking At Closely?

WuXi Biologics (Cayman) Inc. to Report Fiscal Year 2022 Results on Mar 22, 2023

Does WuXi Biologics (Cayman) (HKG:2269) Deserve A Spot On Your Watchlist?

An Intrinsic Calculation For WuXi Biologics (Cayman) Inc. (HKG:2269) Suggests It's 29% Undervalued

Investor sentiment improved over the past week

Is WuXi Biologics (Cayman) (HKG:2269) A Risky Investment?

Now 22% undervalued after recent price drop

Investor sentiment improved over the past week

WuXi Biologics (Cayman) Inc. Announces Demise of Teh-Ming Walter Kwauk, Independent Non-Executive Director, the Chairman of the Audit Committee of the Company and A Member of the Nomination Committee of the Company

CEO & Executive Director recently sold HK$6.0m worth of stock

Wuxi Biologics (Cayman) Inc. Announces Appointments to Strategy Committee

Why WuXi Biologics (Cayman) Inc. (HKG:2269) Could Be Worth Watching

Less than half of directors are independent

With EPS Growth And More, WuXi Biologics (Cayman) (HKG:2269) Makes An Interesting Case

Investor sentiment improved over the past week

Is WuXi Biologics (Cayman) Inc. (HKG:2269) Trading At A 47% Discount?

Investor sentiment deteriorated over the past week